JNJ Strangle Strategy
JNJ (Johnson & Johnson), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NYSE.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
JNJ (Johnson & Johnson) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $554.67B, a trailing P/E of 26.78, a beta of 0.26 versus the broader market, a 52-week range of 147.33-251.71, average daily share volume of 8.0M, a public-listing history dating back to 1943, approximately 138K full-time employees. These structural characteristics shape how JNJ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.26 indicates JNJ has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. JNJ pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on JNJ?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current JNJ snapshot
As of May 15, 2026, spot at $227.34, ATM IV 21.53%, IV rank 54.12%, expected move 6.17%. The strangle on JNJ below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this strangle structure on JNJ specifically: JNJ IV at 21.53% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 6.17% (roughly $14.03 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JNJ expiries trade a higher absolute premium for lower per-day decay. Position sizing on JNJ should anchor to the underlying notional of $227.34 per share and to the trader's directional view on JNJ stock.
JNJ strangle setup
The JNJ strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JNJ near $227.34, the first option leg uses a $240.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JNJ chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JNJ shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $240.00 | $1.22 |
| Buy 1 | Put | $215.00 | $1.52 |
JNJ strangle risk and reward
- Net Premium / Debit
- -$274.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$274.00
- Breakeven(s)
- $212.26, $242.74
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
JNJ strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on JNJ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$21,225.00 |
| $50.28 | -77.9% | +$16,198.50 |
| $100.54 | -55.8% | +$11,171.99 |
| $150.81 | -33.7% | +$6,145.49 |
| $201.07 | -11.6% | +$1,118.99 |
| $251.34 | +10.6% | +$859.51 |
| $301.60 | +32.7% | +$5,886.02 |
| $351.87 | +54.8% | +$10,912.52 |
| $402.13 | +76.9% | +$15,939.02 |
| $452.40 | +99.0% | +$20,965.52 |
When traders use strangle on JNJ
Strangles on JNJ are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the JNJ chain.
JNJ thesis for this strangle
The market-implied 1-standard-deviation range for JNJ extends from approximately $213.31 on the downside to $241.37 on the upside. A JNJ long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current JNJ IV rank near 54.12% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on JNJ should anchor more to the directional view and the expected-move geometry. As a Healthcare name, JNJ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JNJ-specific events.
JNJ strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JNJ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JNJ alongside the broader basket even when JNJ-specific fundamentals are unchanged. Always rebuild the position from current JNJ chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on JNJ?
- A strangle on JNJ is the strangle strategy applied to JNJ (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With JNJ stock trading near $227.34, the strikes shown on this page are snapped to the nearest listed JNJ chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are JNJ strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the JNJ strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 21.53%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$274.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JNJ strangle?
- The breakeven for the JNJ strangle priced on this page is roughly $212.26 and $242.74 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JNJ market-implied 1-standard-deviation expected move is approximately 6.17%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on JNJ?
- Strangles on JNJ are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the JNJ chain.
- How does current JNJ implied volatility affect this strangle?
- JNJ ATM IV is at 21.53% with IV rank near 54.12%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.